Program
romosozumab
Also written as “Romosozumab”, “Romozosumab” and “romosozumab HCP administration with PFS”.
Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Bone Diseases, Metabolic · Osteogenesis Imperfecta · Hip Fractures, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 212 open or running | phase 4since Sep 25, 2023 | May 7, 2009 | Jan 14, 2027phase 1 · NCT07811999 |
| UCB | 10 open or running | phase 3since Sep 23, 2021 | Sep 23, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since May 7, 2009.
- May 24, 2012Phase 3 study in OsteoporosisAmgen · NCT01631214 · 4,093 enrolled · United States, Argentina, Australia and more
- Jan 25, 2013Phase 1 study in Bone Diseases, MetabolicAmgen · NCT01825785 · 48 enrolled
- Feb 19, 2013Phase 3 study in Osteoporosis, PostmenopausalAmgen · NCT01796301 · 436 enrolled · United States, Argentina, Belgium and more
- Apr 15, 2013Phase 1 study in OsteoporosisAmgen · NCT01833754 · 24 enrolled · United States
- Nov 19, 2013Phase 2 study in Osteoporosis, PostmenopausalAmgen · NCT01992159 · 252 enrolled · Japan
- Dec 10, 2013Phase 3 study in Osteoporosis, PostmenopausalAmgen · NCT02016716 · 294 enrolled · United States, Czechia, Poland
- Jun 23, 2014Phase 3 study in Osteoporosis in MenAmgen · NCT02186171 · 245 enrolled · United States, Belgium, Colombia and more
- Jun 2, 2016Phase 3 study in Osteoporosis, PostmenopausalAmgen · NCT02791516 · 67 enrolled · Korea, Republic of
- Jan 30, 2018Phase 3 study in Osteoporosis, PostmenopausalAmgen · NCT03432533 · 283 enrolled · United States, Poland, United Kingdom
- Sep 4, 2020Phase 1 study in Osteogenesis ImperfectaAmgen · NCT04545554 · 25 enrolled · United States, Austria, Germany and more
- Sep 23, 2021UCB's first study: phase 3 study in OsteoporosisNew to UCBUCB · NCT05067335 · 327 enrolled · China
- Jul 24, 2023Phase 3 study in Osteogenesis ImperfectaAmgen · NCT05972551 · 111 enrolled · United States, Australia, Austria and more
- Sep 25, 2023Phase 4 study in Osteoporosis, PostmenopausalAmgen · NCT06079476 · 100 enrolled · India
- Sep 4, 2026Phase 1 study in Healthy ParticipantsAmgen · NCT07811999 · 308 planned · United States, United Kingdom
Ahead
- Jan 14, 2027Primary completion: phase 1 study in Healthy ParticipantsAmgen · NCT07811999
- May 4, 2027Primary completion: phase 3 study in Osteogenesis ImperfectaAmgen · NCT05972551
TargetBeta
“Sclerostin inhibitor”ChEMBL 37, by rule
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07811999Healthy Participants · United States, United Kingdom | 1 | Recruiting | Amgen | Jan 14, 2027 | 308 |
| NCT06079476Osteoporosis, Postmenopausal · India | 4 | Completed | Amgen | Oct 18, 2025 | 100 |
| NCT05972551Osteogenesis Imperfecta · United States, Australia, Austria and more | 3 | Active, not recruiting | Amgen | May 4, 2027 | 111 |
| NCT05067335Osteoporosis · China | 3 | Completed | UCB | Nov 9, 2023 | 327 |
| NCT04545554Osteogenesis Imperfecta · United States, Austria, Germany and more | 1 | Completed | Amgen | Mar 30, 2023 | 25 |
| NCT03432533Osteoporosis, Postmenopausal · United States, Poland, United Kingdom | 3 | Completed | Amgen | Apr 11, 2019 | 283 |
| NCT02791516Osteoporosis, Postmenopausal · Korea, Republic of | 3 | Completed | Amgen | Feb 12, 2018 | 67 |
| NCT02186171Osteoporosis in Men · United States, Belgium, Colombia and more | 3 | Completed | Amgen | Feb 15, 2016 | 245 |
| NCT02016716Osteoporosis, Postmenopausal · United States, Czechia, Poland | 3 | Completed | Amgen | Sep 8, 2014 | 294 |
| NCT01992159Osteoporosis, Postmenopausal · Japan | 2 | Completed | Amgen | Oct 9, 2014 | 252 |
| NCT01833754Osteoporosis · United States | 1 | Completed | Amgen | Feb 19, 2014 | 24 |
| NCT01796301Osteoporosis, Postmenopausal · United States, Argentina, Belgium and more | 3 | Completed | Amgen | May 14, 2015 | 436 |
| NCT01825785Bone Diseases, Metabolic | 1 | Completed | Amgen | Dec 2, 2008 | 48 |
| NCT01631214Osteoporosis · United States, Argentina, Australia and more | 3 | Completed | Amgen | Feb 27, 2017 | 4,093 |
| NCT01588509Osteoporosis · United States | 1 | Completed | Amgen | Nov 21, 2012 | 60 |
| NCT01575834Osteoporosis, Postmenopausal · United States, Argentina, Australia and more | 3 | Completed | Amgen | Dec 14, 2015 | 7,180 |
| NCT01101061Bone Diseases, Metabolic | 1 | Completed | Amgen | Nov 1, 2010 | 31 |
| NCT01081678Hip Fractures · United States, Argentina, Australia and more | 2 | Completed | Amgen | Jun 30, 2012 | 332 |
| NCT01059435Bone Diseases, Metabolic | 1 | Completed | Amgen | Jul 6, 2007 | 74 |
| NCT00950950Bone Diseases, Metabolic | 1 | Completed | Amgen | Aug 19, 2010 | 24 |
| NCT00907296Fracture Healing · United States, Australia, Bulgaria and more | 2 | Completed | Amgen | Mar 6, 2012 | 402 |
| NCT00896532Bone Diseases, Metabolic | 2 | Completed | Amgen | Feb 21, 2011 | 419 |
How it is read
Names in the registry
- “Romosozumab”, 19 entries
- “Romozosumab”, 1 entry
- “romosozumab HCP administration with PFS”, 1 entry
- “Romosozumab 90 mg/mL”, 1 entry
- “Romosozumab 70 mg/mL”, 1 entry
Conditions, from the studies’ own filings
- Osteoporosis, Postmenopausal, 8 studies
- Osteoporosis, 5 studies
- Bone Diseases, Metabolic, 4 studies
- Osteogenesis Imperfecta, 2 studies
- Hip Fractures, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.